⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802994 | 0.70 | — | — | |
| SCHEMBL4040168 | 0.67 | — | — | |
| SCHEMBL5363516 | 0.60 | — | — | |
| SCHEMBL184857 | 0.56 | — | — | |
| SCHEMBL20212016 | 0.56 | — | — | |
| SCHEMBL124148 | 0.56 | — | — | |
| SCHEMBL25425007 | 0.55 | — | — | |
| SCHEMBL149335 | 0.53 | — | — | |
| SCHEMBL2599700 | 0.53 | — | — | |
| SCHEMBL11126570 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-20090054460-A1 | Piperazine derivatives and methods of use | CHEN JIAN J | 2009-02-26 | — | — | US | claimed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | claimed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | claimed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | claimed |
| US-7393852-B2 | Piperazine derivatives and methods of use | AMGEN INC. (US) | 2008-07-01 | — | — | US | claimed |
| EP-1656355-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1878728-A2 | Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders | Amgen Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| EP-1817306-A1 | TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS | Amgen, Inc (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006044412-A1 | NOVEL B1 BRADYKININ RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006044355-A1 | TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | claimed |
| WO-2005061467-A2 | PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS | AMGEN INC. (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | claimed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | claimed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |